In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide.

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

12月25日，翰宇药业发布企业公告消息称，其近日收到美国食品药品监督管理局的通知，由翰宇药业及 Hikma Pharmaceuticals USA, Inc.联合向 FDA ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmac ...

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to ...